$232 BillionThe market capitalization is the market value of the company. It is the sum of the value of all outstanding shares.
$77.45 - $97.30The lowest and highst price in the last 52 weeks.
0.0xThe price-earnings ratio is the ratio between the price per share (stock price) and the earnings per share. It indicates the percentage of the price per share (stock price) that is generated in earnings in the last 12 months.
$0.00 (0.0%)Dividends per share is the amount of dividends paid out to the shareholder of a single share in the last 12 months. The percentage indicates the ratio of the company's annual dividend compared to its current price per share (stock price).
|Market Cap||$232 Billion|
|Enterprise Value||$266 Billion|
|Dividend Yield||$0.00 (0.0%)|
|1 Year Return||+7.0%|
|Outstanding Shares||2.47 Billion|
|Avg 30 Day Volume||12 Thousand|
|Earnings per Share||$0.00|
|Price to Sales Ratio||4.65|
|Price to Book Ratio||4.65|
|Revenue to Enterprise Value||5.33|
|EBIT to Enterprise Value||22.66|
|Total Debt to Enterprise Value||0.14|
|Debt to Equity||0.75|
|Gross Profit||$34.4 Billion|
|Net Income||$7.96 Billion|
|Quarterly Earnings Growth (YoY)||-5.4%|
|Return on Equity||15.75%|
|Return on Assets||6.53%|
|Return on Invested Capital||12.82%|
Novartis AG is a holding company, which engages in the development, manufacture, and marketing of healthcare products. It operates through the following segments: Innovative Medicines, Sandoz, and Corporate. The Innovative Medicines segment researches, develops, manufactures, distributes and sells patented pharmaceuticals, and is composed of two business units: Novartis Oncology and Novartis Pharmaceuticals. The Sandoz segment develops, manufactures and markets finished dosage form medicines as well as intermediary products including active pharmaceutical ingredients. The Corporate segment refers to group management and central services. The company was founded on February 29, 1996 and is headquartered in Basel, Switzerland.
(Novartis) Project brings together Novartis drug discovery and gene therapy expertise and funding support from the Gates Foundation Agreement aims to addressCompanyNewsHQ, 4 months ago
Between Monday and Thursday, Ark Innovation bought shares of Novartis and Regeneron Therapeutics.CNBC, 4 months ago
No summary available.Romania Insider, 4 months ago